Delgocitinib FDA Approval Status
Last updated by Judith Stewart, BPharm on Oct 30, 2024.
FDA Approved: No
Generic name: delgocitinib
Dosage form: Topical Cream
Company: LEO Pharma Inc.
Treatment for: Chronic Hand Eczema
Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor in development for the treatment of moderate to severe chronic hand eczema.
- Chronic hand eczema (CHE) is defined as hand eczema that lasts for more than three months or relapses twice or more within a year. It is characterized by itch and pain, and some patients can also experience erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.
- Delgocitinib works by inhibiting the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.
Development timeline for delgocitinib
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.